Characteristics | Levosimendan group (n = 94) | Placebo group (n = 93) | p value |
---|---|---|---|
Age (months)a | 5 (2,11) | 7 (2,16) | 0.318 |
Gender, female, n (%) | 42 (44.7%) | 41 (44.1%) | 1.000 |
BMI (kg/m2) | 14.83 ± 2.21 | 14.76 ± 2.13 | 0.870 |
BSA (m2) | 0.36 ± 0.17 | 0.39 ± 0.19 | 0.248 |
RACHS classification, n (%)* | Â | Â | 0.146 |
 RACHS 2 | 53 (63.1%) | 67 (72.0%) |  |
 RACHS 3 | 21 (25.0%) | 11 (11.8%) |  |
 RACHS 4 | 9 (10.7%) | 13 (14.0%) |  |
 RACHS 5 | 1 (1.2%) | 2 (2.2%) |  |
Down’s syndrome, n (%) | 3 (3.2%) | 2 (2.2%) | 0.660 |
CPB (min) | 81 ± 34 | 84 ± 30 | 0.479 |
Cross-clamp (min) | 46 ± 23 | 51 ± 22 | 0.163 |